Victoria Lander
Victoria Lander is a market development manager at Nugenesis Technologies, 1900 West Park Drive, Westboro, Massachusetts 01581, USA. Tel. +508 870 7517 vlander@nugenesis.com
Articles
21 CFR Part 11 and Risk Assessment: Adapting Fundamental Methodologies to a Current Rule
May 1st 2004FDA expects a firm that is subject to GxP to develop a risk evaluation of its product and to then mitigate the identified risks. Identified risks may be addressed by technical fixes that effectively eliminate the risks or reduce the likelihood of occurrence and/or severity of consequences to acceptable levels.
Latest Updated Articles
Published: October 11th 2024 | Updated: October 18th 2024
Buy, Sell, Hold: Cell and Gene Therapy - Part 1
Published: September 10th 2024 | Updated: September 18th 2024
CPHI Milan Announces 2024 CPHI Pharma Award Finalists
Published: November 6th 2024 | Updated: November 20th 2024
Automate Aseptic Filling: Closing the System at Full Modularity
Published: November 5th 2024 | Updated: November 20th 2024
Untethered Data: Unifying and Contextualizing Drug Discovery Data
Published: November 8th 2024 | Updated: November 20th 2024
Application of Validation Principles to the Training Quality System: Part 9, Quality Risk Management Hazard Identification
Published: November 4th 2024 | Updated: November 20th 2024
Strategies for Overcoming Common Challenges in Tech Transfer
